KWM
ABBV icon

Kingsview Wealth Management’s AbbVie ABBV Stock Holding History

Kingsview Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-400
Closed -$1K – 911
2021
Q1 		$1K Buy
+400
New +$42.8K ﹤0.01% 842
2017
Q4 		– Sell
-2,400
Closed -$4K – 391
2017
Q3 		$4K Buy
+2,400
New +$183K ﹤0.01% 308

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kingsview Wealth Management's ABBV Position: Q2 2026 in Review

Kingsview Wealth Management increased its AbbVie (ABBV) stake by 0.1% in Q2 2026, buying an estimated $15.1K and bringing the position to 71,689 shares worth $18M. The position accounts for 0.22% of the portfolio, ranked #92.

Kingsview Wealth Management first reported a position in ABBV in Q1 2017 and has held it in 38 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Kingsview Wealth Management held 71,689 shares of AbbVie worth $18M as of Q2 2026.
  • Kingsview Wealth Management bought 70 AbbVie shares in Q2 2026, an estimated $15.1K.
  • AbbVie made up 0.22% of Kingsview Wealth Management's portfolio in Q2 2026, its #92 holding.
  • Kingsview Wealth Management first reported a position in AbbVie in Q1 2017 and has held it in 38 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.